SOME Trial: Sintilimab Plus Chemotherapy for Oligometastatic Esophageal Cancer

148 patient records from a multicenter, prospective, phase II clinical trial investigating a treatment regimen for thoracic esophageal squamous cell carcinoma. The trial, registered with the Chinese Clinical Trial Registry (ChiCTR2500108825), compares outcomes for patients with locally advanced, oligometastatic, and polymetastatic disease. All patients received sintilimab plus platinum-based chemotherapy, with cohorts A and B receiving additional curative-intent local therapy.

Use Cases

• Compare overall survival outcomes based on metastatic burden (oligometastatic vs. polymetastatic) mentioned in the trial design
• Analyze progression-free survival and disease-free survival as secondary endpoints described in the protocol
• Evaluate the efficacy of combining immunotherapy (sintilimab) with chemotherapy and local therapy for specific patient cohorts
• Study patient stratification and outcomes based on protocol-defined assignment to cohorts A, B, and C

Strengths

• Data originates from a prospective, multicenter phase II clinical trial with a defined protocol
• Includes 148 enrolled patients with specific allocation across three cohorts (37, 37, 74)
• Primary and secondary endpoints (overall survival, progression-free survival) are clearly defined

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect geographic bias inherent to the participating trial centers

Provenance

Source

Author Kanghua Zhang, via figshare. Trial registered with Chinese Clinical Trial Registry.

Collection Method

Data collected as part of a prospective, open-label phase II clinical trial.

Freshness

Last updated 2026-05-15 12:40:03; freshness should be verified

Geography

Multicenter trial, likely conducted in China based on registry.